Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Integral Diagnostics Ltd. ( (AU:IDX) ) is now available.
Integral Diagnostics Ltd. announced the issuance of 677 performance rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX, indicating a strategic move to incentivize employees and align their interests with company performance.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Ltd. operates in the healthcare industry, providing diagnostic imaging services. The company focuses on delivering high-quality radiology services across Australia and New Zealand, catering to a wide range of medical needs.
Average Trading Volume: 1,063,185
Technical Sentiment Signal: Buy
Current Market Cap: A$1.01B
For a thorough assessment of IDX stock, go to TipRanks’ Stock Analysis page.